David Ortiz wins Clemente Award, says he’d like to return to Red Sox

11 Comments

David Ortiz, who will be a free agent this winter, said last week that he was open to joining the New York Yankees next season.

On Thursday, while speaking to reporters in St. Louis after winning the Roberto Clemente Award, Ortiz clarified those comments about free agency. The upshot? People made too much about what he said about the Yankees, and he would actually like to return to Boston once the Theo Epstein mess is sorted out and the team finds a new manager.

“Of course, I would like to come back,” he said. “They have a lot of things going on right now. So once they go through all the stuff, GM and managing things, I think they’re going to start talking to the players. So, we’ll see. We’ve got time.”

And what about the Yankees?

“I never said that I would sign with the Yankees. No, no, no, no, no, no, no, no,” he said. “They asked me if I would play for the Yankees. I said I would think about it. But I didn’t confirm to nobody that I would play for the Yankees. I’m still a Red Sox, aren’t I?”

Ortiz is right, of course. All he said was that he would have to think about going to New York if the Yankees showed interest, which seems like a perfectly reasonable way to approach free agency. That being said, he shouldn’t be surprised by the reaction given the nature of the Red Sox-Yankees rivalry.

So there you have it. To sum up: David Ortiz would consider being a Yankee, but would like to stay in Boston. Also, he didn’t say it, but I’m guessing he would play in Seattle or Kansas City if the money was right. OK well, really right.

Now, back to the World Series …

You can follow Bob on Twitter here, or if Facebook is your thing, be his friend here.

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.